Medgenics confirms talks with Baxter on biopump deal
Tissue-based delivery tech developer Medgenics is in talks with Baxter Healthcare about new deal, but says continued focus on Factor VIII is not ‘mission critical’ to biopump platform.
News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs